The Newsroom

Investigations  /  06.30.2020

Investigation of Elanco Animal Health Incorporated

You Have Legal Options

Elanco Animal Health Incorporated (ELAN) Accused of Misleading Shareholders   

On March 24, 2020, Elanco withdrew its previously announced 2020 revenue and earnings per share guidance in light of the coronavirus pandemic. However, Elanco assured investors “the Company is closely monitoring distribution logistics” and that “at this time, Elanco is not experiencing any supply disruption.” Despite these assurances, on May 7, 2020, Elanco announced its first quarter 2020 results revealing revenue of $657.7 million and earnings per share of negative $0.12, reflecting “a reduction of approximately $60 million in channel inventory.” Elanco attributed the disappointing financial results to “distributor performance,” among other things and assured investors the Company would “tighten [its] approach across many facets of [its] distributor relationships.” On this news, Elanco’s share price fell over 13% to close at $19.88 per share.

  • If you would like more information about your rights and potential remedies please send us a message. 

  • Please Note: Neither the submission to nor the receipt of information by Robbins LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

How can we help you?

CONTACT US TODAY | 1 800 350 6003 or [email protected]

Tell us your concerns